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Recent studies have led to considerable advancement in our understanding of the molecular mechanisms that underlie the relentless
cell growth and invasiveness of human gliomas. Partial understanding of these mechanisms has (1) improved the classification for
gliomas, by identifying prognostic subgroups, and (2) pointed to novel potential therapeutic targets. Some classes of ion channels have
turned out to be involved in the pathogenesis and malignancy of gliomas. We studied the expression and properties of K
þ channels
in primary cultures obtained from surgical specimens: human ether a go `-go ` related (hERG)1 voltage-dependent K
þ channels, which
have been found to be overexpressed in various human cancers, and human ether a go `-go `-like 2 channels, that share many of hERG1’s
biophysical features. The expression pattern of these two channels was compared to that of the classical inward rectifying K
þ
channels, IRK, that are widely expressed in astrocytic cells and classically considered a marker of astrocytic differentiation. In our study,
hERG1 was found to be specifically overexpressed in high-grade astrocytomas, that is, glioblastoma multiforme (GBM). In addition,
we present evidence that, in GBM cell lines, hERG1 channel activity actively contributes to malignancy by promoting vascular
endothelial growth factor secretion, thus stimulating the neoangiogenesis typical of high-grade gliomas. Our data provide important
confirmation for studies proposing the hERG1 channel as a molecular marker of tumour progression and a possible target for novel
anticancer therapies.
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Gliomas are the most common brain tumours. Based on
morphology and histological features, they are classified as
astrocytomas (A), oligodendrogliomas (OD), mixed oligoastro-
cytomas (OA) or ependimomas (Ep) (Maher et al, 2001). Each of
the above classes can be further subdivided according to the
grading criteria outlined by the Word Health Organization (WHO;
Kleihues and Cavenee, 2000). Tumour grade is usually considered
the primary determinant of clinical outcome, although histo-
genesis contributes as well. For example, among high-grade
gliomas, anaplastic ODs have a more favourable prognosis than
glioblastoma multiforme (GBM) (i.e. WHO grade IV A). Moreover,
primary (or de novo) GBM, more frequently affecting old patients,
have a worse prognosis than secondary GBM, typically arising in
young patients as a recurrence of a previous, lower-grade lesion.
Therefore, a classification merely based on histopathological
features is inadequate. Creation of a new classification of gliomas,
with prognostic value and based on molecular properties, has
recently been proposed (Huang et al, 2000; Louis et al, 2001;
Rickman et al, 2001; Godard et al, 2003; Nutt et al, 2003). Recent
studies have shed some light on the molecular mechanisms that
underlie gliomagenesis (Maher et al, 2001) and regulate glioma
growth and invasiveness. Particular attention has been given to
neoangiogenesis, typical of high-grade GBM (Godard et al, 2003;
Kitange et al, 2003). According to these studies, primary GBMs can
be distinguished from secondary GBMs by their expression of
genes involved in neoangiogenesis. This kind of understanding
of molecular mechanisms is assuming greater importance in the
design of treatments tailored specifically to each tumour subset.
For example, a promising approach to treatment of gliomas is the
targeting of molecules involved in neoangiogenesis, such as the
vascular endothelial growth factor (VEGF) and its receptors.
An intriguing aspect of the biology of malignant gliomas is that
it is the same ion transport mechanisms that normally control
homeostatic processes such as the regulation of cell volume (Bostel
et al, 2002), proliferation and differentiation (Pancrazio et al,
1999), that often become part of the pathogenesis and malignancy
of these tumours. The expression profile of ion channels is known
to be profoundly altered in glial tumour cells (Bordey and
Sontheimer, 1998; Bubien et al, 1999; Ranson and Sontheimer,
2001; Olsen and Sontheimer, 2004). In some contexts, these
alterations have been shown to trigger relentless growth (reviewed
in Arcangeli and Becchetti, 2006) and invasiveness (Soroceanu
et al, 1999; Ishiuchi et al, 2002; Olsen et al, 2003). In other cases,
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sthe expression profile of specific ion channels may change as a
result of a local reaction to a pathological state, such as trauma,
infection or the tumour itself (Saadoun et al, 2003). A recent report
indicates that, when expressed at the blood–brain barrier at the
tumour site, potassium channels can even restrict the delivery of
anticancer drugs (Ningaraj et al, 2003). On the whole, it appears
that ion channels/transporters, normally functioning to control ion
homeostasis in a healthy brain, may contribute to the establish-
ment of the malignant phenotype of brain tumours. This evidence
points to ion channels as novel molecular markers for malignant
gliomas and as new candidate targets for therapy (Conti, 2004;
Arcangeli, 2005).
The human ether a go `-go ` related (hERG1) channels (KCNH2 or
Kv 11.1, according to the most recent nomenclature) are voltage-
dependent K
þ channels that are overexpressed in human
endometrial adenocarcinoma (Cherubini et al, 2000), myeloid
leukaemia (Pillozzi et al, 2002) and colorectal cancer (Lastraioli
et al, 2004). In addition, they are often overexpressed in neoplastic
cell lines of different origin. Interestingly, in primary cultures from
leukaemia blasts, and in many cell lines, hERG1 inhibition tends to
block cell proliferation (reviewed in Arcangeli, 2005; Arcangeli and
Becchetti, 2005).
To build on these studies, we examined the expression and
properties of hERG1 channels and the functionally related human
ether a go `-go `-like (hELK)2 channels (Miyake et al, 1999; Becchetti
et al, 2002; KCNH3 or Kv 12.2). The expression pattern of these
two channels was compared to that of the classical inward
rectifying (IRK) K
þ channels (KCNJ2 or Kir 2.1), widely expressed
in astrocytic cells, and whose plasma membrane expression is
downregulated in gliomas (Olsen and Sontheimer, 2004).
It emerged that hERG1 channels are specifically overexpressed
in high-grade A, particularly in primary GBM. This finding
prompted us to investigate how hERG1 expression may represent a
selective advantage to glial tumour cells. Due to the significance of
angiogenic factor secretion in conferring high malignancy to
gliomas, and since several studies indicate a role for hERG currents
(IhERG) in neuroendocrine secretion (Rosati et al, 2000; Bauer et al,
2003; Gullo et al, 2003), we sought a functional link between
hERG1 activity and the secretion of angiogenic factors, such as
VEGF.
MATERIALS AND METHODS
Tissue collection
Surgical specimens were obtained from the Istituto Neurologico
Besta of Milano and the Department of Neurosurgery of the
University of Firenze.
Histological examinations
The histological study on tumour samples was performed at the
Neuropathology Section of the Istituto Neurologico Besta, Milano,
and at the Department of Human Pathology and Oncology,
University of Firenze, Firenze. Specimens were fixed in different
solutions (Carnoy’s solution was routinely used for samples
processed in Milano, while 3.7% formalin solution was routinely
used for samples processed in Firenze). All samples were
embedded in paraffin. Histopathological evaluation was performed
on haematoxylin–eosin-stained sections. Pathologists (BP, GLT,
AMB) determined the histological diagnosis using standard
criteria (Buccoliero et al, 2002).
Primary cell cultures
Surgical fragments of brain tumours were collected under sterile
conditions and kept in Dulbecco’s modified Eagle Medium:F12
(DMEM:F12) (1:1) plus 1% penicillin–streptomycin/fungizone
(Hyclone Laboratories, Logan UT), until dissociation. Samples
were first thoroughly minced and then enzymatically dissociated
by a 6h digestion at 371C with collagenase II (Roche Diagnostic,
Mannheim, Germany) 0.05mgml
 1 in DMEM:F12. Dissociated
cells were centrifuged and then resuspended in complete medium
(DMEM:F12, medium supplemented with antibiotics and 10%
foetal calf serum (FCS, Hyclone)) and seeded into either 35mm
Petri dishes (Corning-Costar, Corning, NY) for patch-clamp
experiments, or into 60mm Petri dishes for molecular biology
experiments, or in chamber slides (BD Falcon, Franklin Lakes, NJ)
for immunocytochemical detection of glial fibrillary acidic protein
(GFAP)). After a 24h incubation, cell cultures were rinsed with
sterile PBS, and fresh medium was added. Experiments were
normally performed on cells cultured for less than 5 days, since
glioma cells tend to lose glial and acquire a mesenchymal
phenotype when subjected to long-term culture (McKeever et al,
1991).
Reverse transcription (RT) and polymerase chain reaction
(PCR) amplification
Cells were rinsed twice in cold sterile PBS and lysed in a
guanidinium thiocyanate buffer. Samples were then extracted by
the phenol/chloroform method. Total RNA was quantified by
spectrophotometric analysis and checked for purity and quality by
running a small aliquot on a 1% agarose gel. 1–2mg were reverse
transcribed with Superscript II (Invitrogen, Carlsbad, CA), using
250mM random hexamers, in a 20ml reaction mix. RNAse inhibitor
(1U) (Roche) was used to avoid RNA degradation. The reaction
was carried out following manufacturer’s instructions. Total cDNA
was used as a template for PCR amplification with Herculase
DNApol (Stratagene, Cedar Creek, TX) and each of the primer
pairs reported below. As a quality control on cDNA, PCR
amplification of the messenger relative to the housekeeping gene
gapdh was performed using the following primer pair:
Fw: 50-AACAGCCTCAAGATCATCAGCAA-30
Rev: 50-CAGTCTGGGTGGCAGTGAT-30
(NG 003027, nucleotides 457–564)
Samples positive to gapdh amplification were further analysed
using the following primers:
hERG1 fw: 50-TCCAGCGGCTGTACTCGGGC-30
hERG1 rev: 50-TGGACCAGAAGTGGTCGGAGAACTC-30
(U04270, nucleotides 2171–2746).
helk2 fw: 50-CTGCCCTGCGGGGCACTGTCTG-30
helk2 rev: 50-AGATCTGGGGGCACATTCCATG-30
(NM012284 nucleotides 1802–2516).
Kir 2.1 fw: 50-GTGATTGCCATGAGAGACGGC-30
Kir 2.1 rev: 50-TCTTCCTCCTTTGCTTGTGAGG-30
(U 12507, nucleotides 923–1488).
hEAG fw: 50-CGCATGAACTACCTGAAGACG-30
hEAG rev: 50-TCTGTGGATGGGGCGATGTTC-30
(NM 002238, nucleotides 1032–1510 and NM 172362, nucleo-
tides 1032–1591).
PCR protocols consisted in a 2min initial activation step at
951C, followed by 35 cycles of amplification. Each cycle included
30s at 941C, 1min at the specific annealing temperature (561C for
herg1,6 4 1C for helk2 and 601C for Kir 2.1, gapdh and hEAG) and
1min extension at 681C. Total human brain RNA (Ambion, Austin,
TX) was used as a control for expression of all the above
transcripts. As a control for RNA purity, mock reverse-transcrip-
tion mixes (where RT was omitted) were PCR amplified along with
samples: no unspecific bands, due to genomic DNA contamina-
tion, have ever been observed.
For semiquantitative PCR of VEGF transcripts, RNA was
extracted from U138 cells and reverse-transcribed as above. The
following primers were used, according to Meister et al (1999):
vegf fw: 50-CGAAGTGGTGAAGTTCATGGATG-30
vegf rev: 50-TTCTGTATCAGTCTTTCCTGGTGAG-30
hERG1 channels and glioblastoma multiforme
A Masi et al
782
British Journal of Cancer (2005) 93(7), 781–792 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sThese primers span the insertion/deletion site of human
VEGF165 and amplification of the transcripts encoding the 121-,
165- and 198-amino-acid isoforms yields PCR products of 403, 535
and 607bp. Conditions were the same as those applied for
amplification of channel-encoding genes, except for a 501C
annealing temperature. All primers were tested over a range of
cycle numbers to assure that amplification was still in a logarithmic
phase of visible product increase. For semiquantitative analysis of
the vegf transcript 20, 25, 30 and 35 cycles were performed, while
for gapdh 15, 20 and 25 cycles were performed. A control
amplification on RNA extracted from HUVEC cells was included.
Patch-clamp recordings
Whole-cell currents were recorded from primary cell cultures
obtained from brain tumour specimens, within 3–4 days. Cells
were voltage-clamped at room temperature with an Axopatch 200B
amplifier (Axon Instruments, Foster City, CA, USA). The cell
capacitance and series resistance were compensated (75–85%)
before each stimulation protocol was run. Pipette resistances were
2–5MO. Currents were low-pass filtered at 2kHz and digitised on-
line at 10kHz with pClamp (Axon Instruments) hardware and
software. Data were subsequently analysed off-line with pClamp
and Origin (Microcal Inc., Northhampton, MA, USA) software.
Extracellular solutions were delivered through a nine-hole
(0.6mm), remote-controlled linear positioner placed near the cell
under study. The standard extracellular solution (SES) contained
(mM): NaCl 130, KCl 5, CaCl2 2, MgCl2 2, Hepes-NaOH 10,
glucose 5, pH 7.4. The high K
þ solution had the same composition,
except that the NaCl and KCl concentrations were 95 and 40mM,
respectively. Pipette contained (in mM): K
þ-aspartate 130, NaCl
10, MgCl2 2, CaCl2 1.3, EGTA-KOH 10, Hepes-KOH 10, ATP
(Mg
2þ salt) 1, pH 7.3. The calculated pCa was 7. The
pharmacological compounds were added to the external solution.
The antiarrhythmic drug Way 123,398 (WAY, kindly gifted by
Dr W Spinelli, Wyeth-Ayerst Research, Princeton, NJ, USA) was
used at a concentration of 1mM. All salts and the other drugs were
purchased from Sigma. To measure inward K
þ currents at
practical test potentials, we artificially decreased the Nernst
potential for K
þ (EK) by exposing cells under investigation to
the high-K
þ external solution. Subsequently, we applied voltage-
clamp steps from  140 to þ20mV, preceded by a 10s
conditioning step at 0mV. The long duration of the conditioning
step was required by the slow kinetics of hERG1 channels
(Scho ¨nherr et al, 1999) and is indifferent for IRK. The holding
potential was  60mV.
The IhERG activation curve was obtained from peak tail currents
at  120mV, elicited after 3s conditioning steps from  60 to
Table 1 Clinical–pathological data
Histopathological diagnosis WHO grade Sample no. Sex Age Location of tumour
A I 3 M 21 Chiasma
A I 7 F 12 Right parietal
A II–III 16 F 32 Left frontoinsular
A II–III 17 F 50 Right frontotemporal
A II–III 29 M 38 Left temporal
A (gemistocytic) III 20 F 51 Left temporoparietal
A (anaplastic) III 26 F 51 Mesial temporal
A (anaplastic) III 30 F 60 Right frontolateral
GBM IV 1 M 57 Right parietal
GBM IV 2 F 72 Right frontal
GBM IV 8 F 69 Left occipital
GBM IV 10 F 75 Right parietoccipital
GBM IV 11 M 44 Right frontoparietal
GBM (Sec) IV 12 M ND Parietal
GBM (Gliosarcoma) IV 13 M 50 Right occipital
GBM (Sec) IV 14 F 46 Right frontal
GBM IV 15 M 67 Right parasagittal
GBM IV 5 F 67 Right frontoccipital
GBM IV 6 M 58 Right temporoccipital
GBM IV 18 F 53 White matter and thalamus
GBM IV 19 M 47 Left temporal
GBM IV 22 F 78 Left temporoparietal
GBM (Sec) IV 23 F 37 Left frontoinsular
GBM IV 24 M 37 Right temporal
GBM (Sec) IV 28 M 31 Left frontal
GBM IV 31 M 45 Left temporoinsular
GBM IV 32 F 59 Left frontal
GBM IV 33 M 53 Left frontotemporal
GBM IV 34 F 68 Left parietal
GBM IV 36 M 61 Right temporoccipital
GBM IV 38 M 45 Left occipital
GBM IV 39 M 69 Right parietal
GBM IV 40 F 82 Left parietal
GBM IV 41 F 74 Left fronto-insular
OD II 9 M 70 Right frontotemporal
OD II 21 F 74 Right frontal
OD II 37 M 50 Left frontotemporal
OA II–III 27 M 47 Left parietoccipital
OA III 25 F 66 Left temporal
Ep II 4 F 26 IV ventricle
Ep III 35 M 33 IV ventricle
A¼astrocytoma; GBM¼glioblastoma multiformis; OD¼oligodendroglioma; OA¼oligoastrocytoma; Ep¼ependimoma; Sec¼Secondary; M¼male; F¼female.
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sþ 40mV. The resting potential (Vrest) of U138 and A172 glioma
cell lines was measured in SES, in open-circuit mode.
The effect of WAY on IhERG in different experimental conditions
was tested on HEK-hERG1 stably transfected cells (Lastraioli et al,
2004). Whole-cell currents were studied by using a two-step protocol
(Hofmann et al, 2001). Conditioning steps at 0 and  70mV (lasting
10s) were followed by an 80ms step, at  120mV. Stock solutions of
WAY were prepared in distilled water at the concentration of 5mM.
The inhibitor was applied to the cells (1) immediately after diluting
in SES; (2) after diluting in the same culture medium used for VEGF
secretion experiments (CM; see below), and incubating for 15min, at
371C, in 5% CO2; (3) after diluting in CM and incubating for 24h, at
371C, in 5% CO2 in the culture plates containing the cells (CM 24h).
For each condition, two different WAY concentrations (1 and 40mM)
were tested. The effect of WAY is reported as percentage inhibition,
calculated as 1 (IhERGWAY/IhERGSES) 100, where IhERGWAY and
IhERGSES are the IhERG values measured in the presence or in the
absence of WAY (i.e. in SES), respectively.
Immunohistochemistry (IHC)
For hERG1 detection, an anti-hERG1 antibody produced in our
laboratory (now available from Immunological Sciences, Roma)
was used at 1:200 dilution. Antigen retrieval and staining
conditions were the same as those reported in Lastraioli et al
(2004). hERG1 immunochemical detection was carried out using
commercially available kits (PicTure Plus kit, Zymed Laboratories,
CA, USA). For GFAP and NF IHC, we used the method previously
described in Buccoliero et al (2002). In this case, immunodetection
was carried out using standard streptavidin–biotin technique and
performed on NEXES automated immunostainer. Antibodies were
the following: mouse anti-GFAP monoclonal (ZCG29) prediluted,
Zymed Laboratories, CA, USA; mouse anti-NF polyclonal (clones:
FNP, DA2, RMd020.11), 1:30 dilution, Zymed Laboratories, CA,
USA. Microwave antigen enhancement was utiliSed for anti-GFAP
and -NF antibodies. For all the above antibodies, diaminobenzi-
dine (DAB, Zymed Laboratories, CA, USA) was used, so that
antigen-expressing cells were distinguished from the negative ones
because of the presence of a brown to black precipitate.
Cell culture and VEGF detection
U138 and A172 cells (kindly provided by Dr A Colombatti, Centro
di Riferimento Oncologico, Aviano) were routinely cultured in
DMEM high glucose plus 10% FCS (Defined, Hyclone). The
detection of hERG1 channel by protein extraction and Western
blotting was performed as reported in Lastraioli et al (2004). For
testing VEGF secretion, cells were seeded into 24-well cell clusters
at 3 10
5cells per well in Opti-Mem (Invitrogen). After 48h, cell
culture medium was changed and WAY or E4031 was added to the
final concentration reported in the legend to Figure 6. After a 24h
incubation, the medium was collected and used for measurement
of secreted VEGF (DuoSet ELISA Development System, R&D
Systems, Wiesbaden, Germany), or bFGF (Quantikine FGF basic
Immunoassay, R&D Systems, Wiesbaden, Germany). Cells were
subsequently detached and counted.
Statistics
Data are given as average values7standard errors of the mean
(s.e.m.), with the number of cases reported within parentheses. When
necessary, a Student’s t-test was applied to test for significance.
RESULTS AND DISCUSSION
A total of 41 cases of glioma were enrolled in the present study.
Their clinical–pathological characteristics are reported in Table 1.
Among them, 19.5% were Grade I–III As, 63.4% were GBMs,
12.2% were ODs or OAs, and 4.9% were Eps. As controls, we
included five samples of normal brain tissue: three of them were
obtained from patients operated on for untreatable epilepsy, two
were fragments of normal brain tissue external to the tumour
mass, from glioma patients. Following excision, tumour fragments
were immediately dissociated and cultured as described in
Materials and Methods. The glial identity of our cultures was
assessed by immunofluorescence staining for GFAP, within 2 days
of seeding. Only primary cultures showing homogeneous staining
for GFAP were considered.
K
þ currents in primary human gliomas
Several types of ion channels have been described in gliomas
(Bordey and Sontheimer, 1998; Bubien et al, 1999; Ranson and
−120
−80
−40
1.5 nA
Control Cs+ 20 mM
Recovery from Cs+ WAY 1 M 
Control – Cs+
200 ms
Control – WAY 1 M
0
−140
+20
Figure 1 IIRK currents in non-neoplastic tissue. Whole-cell current traces
elicited by the stimulation protocol shown in the inset, in the absence
(control) or presence of the indicated K
þ channel inhibitors. The
extracellular solution contained 40mM K
þ, giving an Ek around  30mV.
Cells were conditioned at 0mV for 10s, before applying each test pulse.
The holding potential was  60mV. Top panels: by subtracting the aspecific
currents remaining after Cs
þ treatment (top panels), we obtained the pure
inward component of IIRK. Note the large increase in membrane currents at
Vrest values negative to Ek, in both ‘Control’ and ‘Control–Cs
þ’ traces.
Bottom panels: by subtracting the currents in the presence of WAY from
the control currents, we isolated hERG components, which turned out to
be negligible in healthy tissue.
Table 2 Statistics of IIRK and IhERG in controls and glioma cases
Grade N cases (N cells)
Average current
expression (%)
Current density
(pApF
 1)
IIRK
Controls 4 (42) 30711  22.074.4 (11)
AI–III 3 (31) 22714  11.373.7 (6)
GBM 12 (153) 2874  12.471.7 (40)*
OD/OA 2 (16) 29  4.470.7 (4)*
IhERG
Controls 0 NA NA
AI–III 1 (6) 17 ND
GBM 11 (108) 3578  7.8471 (24)
OD/OA 0 NA NA
IhELK2
Controls 0 NA NA
AI–III 1 (4) 25 ND
GBM 3 (45) 2273  17.476 (9)
OD/OA 0 NA NA
N cases¼number of cases in which the indicated K
+ current was detected; average
current expression¼the fraction of cells showing the indicated current was
calculated for each case and the results thus obtained were averaged; current
density¼average current density at  100mV; ND¼not determined; NA¼not
applicable. Cell count is reported in parentheses. *Significantly different from the
controls (0.01oPo0.05).
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sSontheimer, 2001; Olsen and Sontheimer, 2004). As described in
the Introduction, we sought IRK-type inwardly rectifying currents
(IIRK), and hERG (IhERG), or hELK2 (IhELK2) currents. IRK is a
strong inward rectifier and thus is easier to detect at a membrane
potential (Vm) more negative than Ek. On the other hand, hERG
(hereafter referred to as hERG1) and hELK2 channels are voltage-
dependent outward rectifiers, structurally related to the Shaker
family of K
þ channels (Warmke and Ganetzky, 1994). However,
they are easier to detect when current is flowing inward as well,
since large ‘tail currents’ can be revealed on repolarisation after
conditioning at VmX0mV. During the conditioning step, hERG1
(or hELK2) activates and rapidly inactivates. On repolarisation, the
inactivation is removed within milliseconds, revealing a large tail
current which decays with a relatively slow kinetics, since the
deactivation process is about two orders of magnitude slower
than recovery from inactivation (for details on hERG1/hELK2 in
cell lines and tumours, see Faravelli et al, 1996; Becchetti et al,
2002). To magnify the K
þ currents at practical Vm’s, we usually
applied our stimuli in the presence of 40mM external potassium
(giving a Nernst potential around  30mV). A typical example of
our experimental procedure for measuring whole-cell currents in
non-neoplastic tissue is illustrated in Figure 1. Negligible currents
were observed at Vm more positive than EK, whereas robust inward
currents appeared around  40mV. Subsequent application of 1mM
WAY (a specific inhibitor of hERG channels, when used at this
concentration) had no effect, suggesting that the inward current
does not contain any hERG component. Uncompensated capaci-
tive transients and linear leak were subtracted by using Cs
þ
concentrations between 5 and 20mM. The current/voltage relation
obtained in this way is quasi-linear at Vm more negative than EK.
We tested five samples of healthy tissue. Four of them expressed
measurable IIRK. On average, the percentage of cells showing
IIRK in each sample was 30711%, with a current density of
 2274.4pApF
 1,a t 100mV. The statistics for K
þ currents in
controls and gliomas are given in Table 2. No evidence was found
for IhERG or IhELK2 in healthy tissue. The distribution of IIRK and
the other K
þ currents according to tumour grade is given in
Figure 4 (white bars), along with the distribution of the
corresponding transcripts (black bars). The comparison of the
two sets of data is discussed below.
Figure 2 (panel A) shows typical IIRK from glioma cells. The I/V
curve was generated by plotting the average normalised peak
−−− 60 40 20 0 20 40
–120 –80 –40
–120 –80 –40
Control – Cs+
0.75
0.25
0.50
1.0
Vm (mV)
–140
+20 0
Control – WAY WAY 1 M  Control
50 ms
150 pA
100 ms
1 nA
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Figure 2 IIRK and IhERG in astrocytoma cells. (A) Representative whole-cell IIRK traces, measured from glioma cells, by using the procedure described in
Figure 1. The stimulation protocol is shown in the inset. The conditioning step at 0mV lasted 10s. Holding potential was  60mV. IIRK was isolated by
subtracting the current recorded in the presence of Cs
þ from the total current. In this astrocytoma case, no evidence for IhERG was found. The panel on the
right plots the average normalised peak currents as a function of the test potential, from four experiments. (B) Whole-cell IhERG traces, from a different
astrocytoma case, elicited by using the same stimulation protocol illustrated in panel A. IhERG was isolated by subtracting the current obtained in the presence
of 1mM WAY from the total current. The panel on the right plots the corresponding I/V curve. Data points are average normalised peak currents plotted as a
function of the test potential. Currents were measured in five cells from the same case. (C) Whole-cell tail IhERG at  120mV, elicited from 3s conditioning
pulses from  60 to þ 40mV, as shown in the inset. Pure IhERG was isolated by applying 1mM WAY. Peak tail currents were estimated by extrapolating the
currents at  120mV to the start of pulse (as indicated in the ‘Control–WAY’ panel). In this way, we corrected for the partial deactivation occurring before
the fast recovery from inactivation is complete. Data points are average maximal tail current values at  120mV, plotted as a function of the conditioning
potential, measured in three experiments from the same glioma case.
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scurrents from four cells cultured from the same glioma case, as a
function of test potential. Different samples gave similar results.
The percentage of tumour cases expressing IIRK was 50% in As,
57% in GBMs, 67% in OD/OAs and 100% in Eps (Figure 4). Among
these, the average percentage of cells showing IIRK was around
20–30%, irrespective of tumour grade, a value comparable to that
observed in the controls. However, the corresponding current
densities were significantly lower in GBM and OD/OA, compared
to controls (Table 2).
IhERG was isolated by applying the same stimulation protocol
both in the absence and presence of 1mM WAY. The current
recorded in the presence of the inhibitor was then subtracted from
the total current, to reveal a WAY-sensitive component showing
the typical kinetics of IhERG (Figure 2, panel B). The corresponding
I/V curve was generated from five cells cultured from the same
glioma case. The IhERG activation curve for glioma cells was
obtained from tail currents at  120mV, after 3s conditioning
steps from  60 to þ40mV. The duration of the conditioning
steps is an acceptable compromise between the necessity of
applying long conditioning steps for achieving steady-state
conditions and the practical need for mantaining the duration
of each experiment within reasonable limits to avoid cell damage
(Scho ¨nherr et al, 1999). Typical current traces are shown in
Figure 2 (panel C). Once again, IhERG was isolated by applying
WAY. The corresponding activation curve was obtained from three
cells of the same glioma. For IhERG also, different samples gave
similar results. An alternative approach to distinguish IIRK from
IhERG or IhELK2 is application of 100mM Cs
þ or Ba
2þ. Such
concentrations are ineffective on hERG/hELK2 channels (Arcangeli
et al, 1995; Becchetti et al, 2002), but strongly inhibit IRK. The
latter procedure is particularly useful to isolate IIRK from IhELK2,
which is insensitive to WAY. The isolation and the functional
properties of IhELK2 expressed in human astrocytoma cells have
been recently described by us (Becchetti et al, 2002) and will not be
reproduced here. In general, there was no overlap of IIRK and IhERG.
In the samples that expressed both, most of the cells that we tested
showed either the former or the latter. In GBM, in particular,
among the cells expressing at least one K
þ current type, 50%
expressed IIRK, 42% expressed IhERG and 8% expressed both.
Finally, three out of 21 glioma cases showed IhELK2 that was
expressed in about 22% of the tested cells, with a current density of
 17.476pApF
 1 and no overlap with IhERG (Table 2).
K
þ channel transcript expression in primary human
gliomas
The electrophysiological data show that the ion channels under
investigation are expressed on the plasma membrane and present
usual properties. It was however necessary to complement this
biophysical evidence with molecular data. mRNA and protein
expression patterns do not always fully overlap; thus, a study based
on mere electrophysiological analysis could underestimate the
importance and utility of these marker gene. In addition, RT–PCR
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Figure 3 Reverse transcription–PCR of Kir 2.1, herg1 and helk2
transcripts in a representative pool of glioma samples. RNA extraction,
RT and PCR amplification of the three transcripts was performed as
reported in Materials and Methods. Only samples where a good
amplification of the housekeeping gene gapdh (not shown) was achieved
were processed for further analysis. DNA marker: 100bp (New England
Biolabs); the ‘no-RT’ lane contains a sample of RNA added to the PCR
reaction mixture without previous RT. Lane labelled ‘Brain’ refers to total
human brain RNA (see Materials and Methods). (A) Kir 2.1 transcript; (B)
herg1 transcript; (C) helk2 transcript.
Controls AI–III GBM OD-OA Ep
0
20
40
60
80
100
IIRK
Kir2.1
IIRK/Kir2.1
IhERG/herg1
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
a
s
e
s
Controls AI–III GBM OD-OA Ep
0
20
40
60
80
100
 IhERG
herg1
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
a
s
e
s
Controls AI–III GBM OD-OA Ep
0
20
40
60
80
100
 IhELK2
helk2
IhELK2/helk2
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
a
s
e
s
A
B
C
Figure 4 Correlation of the expression of IIRK, IhERG, IhELK2 and the
corresponding transcripts with tumour grade, in primary gliomas. Bars
represent the percentage of cases expressing the indicated K
þ current
(white bars), or the corresponding transcript (black bars), among the
indicated tumour classes. Data were obtained by patch-clamp for K
þ
currents and RT–PCR for transcript expression (see text). Panels A–C
show the results obtained for IIRK/Kir 2.1, IhERG/herg1 and IhELK2/helk2,
respectively. Controls: normal cases; AI–III: astrocytoma WHO grade I–III;
GBM: glioblastoma multiforme, WHO grade IV; OD: oligodendroglioma;
OA: oligoastrocytoma; Ep: ependimoma.
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sallows the molecular identification of the ion channels responsible
for the ion currents recorded by patch-clamp investigation. To
address these issues, we performed an RT–PCR survey of the most
likely candidate genes: Kir 2.1, a molecular component of IIRK,
known to be highly expressed in cortical astrocytes (Olsen and
Sontheimer, 2004), herg1, a molecular component of IhERG, the
member of the herg family most frequently expressed by tumour
cells (Crociani et al, 2003) and helk2. Representative examples of
the PCR-amplified transcripts are reported in Figure 3.
Figure 4 summarises the expression of the three potassium
channel-encoding genes according to grade (black bars). Kir 2.1
transcript was expressed in 80% of the controls, 40% of the As,
90% of GBMs, 70% of OD/OA and 100% of the Eps, with no
obvious relation to tumour grade (Figure 4, panel A). On the other
hand, herg1 transcript showed a considerably lower overall
expression, except that in high-grade gliomas (Figure 4, panel
B). Finally, the helk2 transcript was detected in a relatively low
percentage of cases, with no clear relation to tumour types
(Figure 4, panel C).
Comparison of K
þ current and transcript expression
Results obtained with patch-clamp and RT-PCR were, generally, in
good agreement. IRK was expressed in the vast majority of normal
and glioma cases examined, irrespective of the histotype and
WHO grade. This suggests that this channel type is unlikely to play
a critical role in gliomagenesis or tumour progression. IRK
expression may actually be inversely related to neoplastic
transformation. In fact, in GBMs, Kir 2.1 was detected in 95% of
the cases, whereas a detectable IIRK was only found in 57% of the
GBM tested, with a current density significantly lower than in the
controls (Table 2). Our results are consistent with those reported
Figure 5 Immunohistochemical detection of hERG1 protein in gliomas and normal brain tissue. Sample preparation, antibodies used and IHC procedures
are reported in Materials and Methods. (A) Immunohistochemistry with anti-hERG1 antibodies in a GBM; (B) IHC with anti-hERG1 antibodies in an OD;
note the lack of staining in neoplastic oligodendrocytes compared to the positive staining of neurons entrapped in the neoplastic lesion; (C) IHC of a normal
brain sample using anti-hERG1 antibodies; c0 ¼GFAP staining (note the positive astrocytes); c00 ¼NF staining (note the positive neurons). Bar¼50mm.
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sby Olsen and Sontheimer (2004), who found a reduction of IIRK in
glioma cell lines, due to diminished translation and mislocalisation
of the Kir 2.1 protein. Our data suggest that such a diminished
translation (or mislocalisation) of IRK-type channels occurs not
only in high-grade glioma cell lines but also in tumour-derived
GBM cells. Therefore, downregulation of IRK may be seen as a
distinctive feature of all the cycling and immature cells of glial
origin, most prominent in highly malignant cells.
Our results on hERG1 show that mRNA expression and IHERG
detection showed the same pattern, with increased expression in
more malignant gliomas. Our observations also suggest that,
unlike Kir 2.1, hERG1, when present at the mRNA level, is
probably correctly expressed in the membrane, although we lack a
comparison with IhERG density in the controls (Table 2).
The results on hELK2 seem also consistent. The only
discrepancy was that the transcript expression in the control
sample was not accompanied by IhELK2 detection. This may be
simply due to the limited sampling possible with patch-clamp
technique.
Thus, similarly to what we reported on colorectal cancers,
hERG1 channel expression was higher in tumour glia and
correlated with an aggressive phenotype.
IHC for hERG1
To exclude the possibility that hERG1 expression was an artefact
due to culturing conditions, we have tested whether the channel
protein was expressed in primary GBM in situ, by using anti-
hERG1 antibodies on those cases where histological sections were
available. The antibodies had been previously tested in human
colorectal cancers (Lastraioli et al, 2004). Representative photo-
graphs are shown in Figure 5. Panel A shows the pattern of hERG1
protein expression in a GBM (case no. 10 in Table 1), in which
both herg1 gene expression and IhERG had been detected. The
localisation of hERG1 in the cytoplasm of neoplastic glial cells is
apparent and evidenced as a brown staining. Panel B shows an OD
case (no. 37 in Table 1) that had neither herg1 gene expression nor
IhERG and, consistently, no immunoreaction. It is interesting to
notice that the few neurons entrapped in the tumour lesion, which
are easily recognisable by their nuclei, showed a positive
cytoplasmic staining for the hERG1 protein. The same pattern of
hERG1 expression (neurons positive and glial cells negative) also
occurs in normal brain tissue. This can be seen in panel C, which
illustrates an area of normal tissue from outside of the tumour
boundaries. Neurons were identified by staining with an NF
antibody (c00) and were also positive for hERG1, while astrocytes
(GFAP-positive cells in inset c0) showed no sign of hERG1
expression.
The immunohistochemical data support our conclusion that: (1)
hERG1 channel is more frequently expressed in human gliomas;
(2) the frequency of channel expression correlates with tumour
grade; (3) the channel is absent in normal human glial cells. We
suggest that herg1 gene and the corresponding protein can be
conceivably employed as markers of tumour progression in glial
tumours, in analogy with what we have reported in colorectal
cancers.
IhERG inhibition reduces VEGF secretion in glioblastoma
cell lines
We noticed that the few GBMs negative for hERG1 expression were
secondary (Sec) cases, arising from previous As of lower grade.
Interestingly, primary GBMs can be distinguished from secondary
GBMs for their expression of angiogenesis-related genes (Godard
et al, 2003). We asked whether the two findings may be linked and
we made the hypothesis that HERG1 channel’s activity is involved
in the regulation of angiogenesis in gliomas, possibly by affecting
the secretion of angiogenic factors, such as VEGF.
To build on the correlative evidence, we determined the amount
of VEGF secreted by the GBM cell lines U138 and A172, after
blocking IhERG. Preliminarily, we examined the expression of Kir
2.1, herg1, helk2 and heag transcripts in both cell lines. hEAG was
included in the screen because it is expressed in human primary
gliomas (Patt et al, 2004), and because hERG channel inhibitors
also block hEAG currents at high concentrations (Gessner and
Heinemann, 2003; Gessner et al, 2004).
It emerged that both U138 and A172 cells expressed Kir 2.1 and
hEAG transcripts, but only U138 cells expressed herg1 as well as
helk2 (Figure 6A).
The finding that herg1 is expressed in U138 cells only was
confirmed at the protein level. Western blotting performed on both
cell lines and on hERG1-transfected HEK 293 cells, for control,
confirmed that only U138 cells expressed the hERG1 protein
(Figure 6B). The mean Vrest of U138 cells was  18mV, which is
similar to the values reported for hERG1-expressing tumour cells
(Arcangeli et al, 1995; Scho ¨nherr et al, 1999). Moreover, WAY
induced a dose-dependent Vrest depolarisation (Table 3), similarly
to that we normally observed in HEK-hERG1 cells. Conversely,
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herg1
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A Brain U138 A172
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135 kDa
Figure 6 K
þ channel expression in glioma cell lines. (A) Expression of
K
þ channel transcripts. Reverse transcription–PCR was performed on
RNA extracted from U138 and A172 cells. Brain cDNA was used as a
positive control. Note that in the sample ‘brain’ two PCR bands relative to
heag were detected, the lower corresponding to the so-called heag1 (NM
002238), the upper corresponding to the longer isoform of the gene
(known as heagb or transcript variant 1, NM 172362). The two cell lines
expressed only the lower band. Lower panel, RT–PCR of the control gene
gapdh, from the samples above. (B) Western blotting with anti-hERG1
antibody of herg1-transfected HEK 293 cells (HEK-hERG1), U138 cells and
A172 cells.
Table 3 Effect of WAY on Vrest of U138 and A172 glioma cells
Cell line
Vrest (mV)
Control
conditions
Vrest (mV) (1lM
WAY)
Vrest (mV) (40lM
WAY)
U138  1873 (7)  1272 (7)  672 (7)
A172  2272 (7)  2471 (7)  2272 (7)
Vrest and its variation after application of 1 and 40mM WAY were determined as
reported in Materials and Methods. Values are means7s.e.m.; cell count is reported
in parentheses.
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sA172 showed a Vrest value around  23mV that was insensitive to
WAY (Table 3).
Furthermore, we determined the dose dependence of WAY
inhibition on IhERG, in the experimental conditions adopted for
measuring VEGF secretion. In fact, the efficacy of hERG blockers
might be altered by protein binding of the drug (Webster et al,
2001), or perhaps progressive degradation during long incubation.
Thus, we tested the efficacy of WAY on IhERG after diluting the
drug: (1) in SES, normally used for our patch-clamp experiments;
(2) in the culture medium used for growing glioma cells during
secretion experiments (CM); (3) in CM medium preincubated for
24h in the same dishes containing the cells (CM 24h). These
experiments were carried out on our HEK-hERG1 stable cell line.
IhERG was studied as tail current at  120mV, after conditioning for
10s at 0mV (to produce maximal activation), and, subsequently, at
 70mV (to produce strong current deactivation, as further control
that we were specifically measuring IhERG). As reported in Figure 7,
1mM WAY produced almost complete inhibition only when diluted
in SES (average percentage IhERG block was 9072%). On the other
hand, the effect of 1mM WAY was drastically reduced after dilution
in CM or CM 24h. On the contrary, 40mM WAY was strongly
effective in all the experimental conditions that we have applied.
The above preliminary tests suggest that U138 and A172 cells are
suitable models for the study of the dependence of proangiogenic
factor secretion on hERG1 channel block. Since U138 cells express
functional hERG1 channels and A172 cells do not, the latter can be
used as negative controls when studying the sensitivity of VEGF
secretion to WAY treatment. In addition, high concentrations of
WAY must be used when cells are tested after 24h incubation in
culture medium.
Finally, we studied the effect of blocking IhERG on VEGF
secretion by the above GBM cell lines. Secretion was measured
after a 24h incubation of U138 and A172 cells in the appropriate
culture medium (see Materials and Methods), in the presence of
increasing concentrations of WAY (Figure 8). U138 cells secreted
VEGF into the culture medium and this secretion was inhibited by
WAY in a dose-dependent manner, with a roughly 50% inhibition
at 40mM (panel A). Conversely, WAY did not inhibit VEGF
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Figure 7 WAY inhibition of IhERG in different experimental conditions. Whole-cell IhERG traces were studied as tail currents at  120mV (for 80ms),
preceded by 10s conditioning steps at 0 and  70mV, as shown in the inset. Currents were measured in the absence (control) or presence of the indicated
concentration of WAY. (A) Effects of 1 and 40mM WAY diluted in (1) SES (upper panels); (2) culture medium incubated 15min at 371C, 5% CO2 (CM,
middle panels); (3) CM incubated 24h in the dishes containing the cells, at 371C and 5% CO2 (CM 24h, lower panels). (B) Percentage of IHERG block,
calculated as explained in Materials and Methods, in the experimental conditions indicated in (A).
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ssecretion in A172 cells (panel B). Our data strongly suggest that
the effect of WAY on VEGF secretion of glioma cells is due to
specific inhibition of IhERG, for two reasons. First, secretion is
only inhibited in glioma cell lines that express functional hERG1
channels. Second, the dose–response of VEGF secretion to WAY
parallels the response of IhERG to WAY in culture conditions
(Figure 7). This conclusion is further supported by the observation
that treatment with 5mM E4031, another specific hERG1 channel
blocker, produced a partial inhibition of VEGF secretion only from
U138 cells (compared to the null effect of E4031 on A172 cells,
reported in panel B). It is worth noting that the effects of hERG
channel blockers in this model were not accompanied by any effect
on cell proliferation (see legend to Figure 8), such as that occurring
in other hERG1-positive cell lines (Arcangeli, 2005; Arcangeli and
Becchetti, 2006).
The effect of WAY was specific to VEGF secretion; in addition
to VEGF, bFGF is also secreted by U138 cells, although in lower
amounts; however, its secretion was insensitive to WAY (inset to
panel A). The apparent specificity of WAY to VEGF secretion
led us to investigate the possible mechanisms of this inhibition.
Since the regulation of VEGF secretion has been attributed to the
modulation of transcription in multiple cell types including glioma
cells (Steiner et al, 2004), a semiquantitative RT–PCR of vegf
(corresponding to VEGF121 and VEGF165) transcripts in U138 cells
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Figure 8 Vascular endothelial growth factor secretion in U138 and A172 glioma cell lines. (A) Effects of WAY and E4031 on VEGF secretion in U138
cells. The amount of VEGF secreted into the medium was determined with an ELISA performed in triplicate (see Materials and Methods) after cells were
incubated for 24h in serum-free medium. The kit used allows detection of both VEGF121 and VEGF165. WAY and E4031 were added at time zero, at the
final concentrations indicated below. Values are expressed as pg of secreted VEGF/10
3 cells during 24h incubation. The number of cells per well was the
following: Control: 5.9870.59 10
5 (n¼11); WAY 1mM: 6.3170.49 10
5 (n¼3); WAY 5mM: 5.1671.12 10
5 (n¼5); WAY 20mM: 5.0971.08 10
5
(n¼4); E4031 5mM: 7.5870.5 10
5 (n¼3). Data reported are means7s.e.m. of three to five separate experiments, each carried out on triplicate samples.
*Significantly different from the control (Student’s t-test for paired samples): WAY 5mM: P¼0.03; WAY 20mM: P¼0.01; WAY 40mM: P¼0.003. Inset: bFGF
secretion in U138 cells in the absence or presence of WAY. The same supernatants as those used for VEGF measurement in panel A were used for the
detection of the secreted bFGF, using an ELISA (see Materials and Methods). Note the different amount of secreted bFGF as compared to VEGF. (B) Effect
of WAY and E4031 on VEGF secretion in A172 cells. Vascular endothelial growth factor was quantified as reported in (A). WAY (5 and 20mM, final
concentrations) and E4031 (20mM, final concentration) were added at time zero. The number of cells per well was the following: Control: 2.2170.03 10
5
(n¼3); WAY 5mM: 2.1870.15 10
5 (n¼2); WAY 20mM: 2.1870.04 10
5 (n¼2); E4031 5mM: 2.06 10
5 (n¼1). Data reported are means7s.e.m. of
two to three separate experiments, each carried out on triplicate samples. It is worth pointing out that the difference in the amount of basal VEGF secretion
between U138 and A172 cells can be attributed to the different cell size. (C) Semiquantitative analysis of vegf mRNA expression after WAY addition. Vegf
expression was determined after 24h of cell incubation in the absence or presence of increasing concentrations of WAY (5, 20 and 40mM). PCR conditions
were adjusted in order to determine the number of cycles corresponding to the exponential phase of amplification, when semiquantitative analysis is
possible. Densitometry was performed with Scion Image software by comparing the intensity of vegf (25 cycles) and gapdh (20 cycles) PCR products. Vegf
expression was inhibited by approximately 30% by treatment with 40mM WAY.
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swas performed under control conditions and in the presence of
increasing concentrations of WAY (Figure 8, panel C). gapdh was
used as a reference for semiquantitative analysis. A dose-
dependent inhibition of transcription of both VEGF165 and
VEGF121 was observed in U138 cells treated with WAY, with a
30% reduction when using the highest concentration (40mM) of the
hERG inhibitor.
We propose that hERG1 channel activity, and the channel’s
overexpression in highly malignant tumours, contributes to
regulating the production/secretion of angiogenic factors from
glial tumour cells, in particular of VEGF, and that this regulation
may rely on the modulation of vegf transcription levels.
CONCLUDING REMARKS
The data reported in this paper lead us to conclude that herg1 is
expressed, and the corresponding IhERG is present, in glial
tumours, especially in high-grade astrocytic tumour, namely
GBM. In contrast, IhERG and the corresponding gene turned out
not to be significantly expressed in the controls, that is, normal
human astrocytes, either in culture or in histological sections.
The expression of the herg1 gene in human glial tumours has
also been recently reported by Patt et al (2004). These authors,
however, found that the transcript expression was lower in high-
grade and higher in low-grade gliomas, especially in the control.
The discrepancy between these data and ours may be traced back
to the fact that Patt and co-workers tested herg1 transcript from
RNA extracted from the whole tissue. Since hERG1 channels are
known to be expressed in neurons throughout the mammalian
brain (Saganich et al, 2001; Polvani et al, 2003; see Figure 3), it is
not surprising that a brain sample shows relatively strong hERG1
expression. To overcome this problem, we have compared acutely
established normal astrocytes and glioma cell cultures, mostly
expressing the glial phenotype (as evidenced by the GFAP
staining).
The increased hERG1 expression in high-grade gliomas may
imply that hERG1 expression correlates with tumour progression.
In addition, we found little overlap of IIRK and IhERG in GBM,
which usually had either the former or the latter. This suggests that
the carcinogenic process may select for a malignant population
which upregulates hERG1 and downregulates the expression of
IRK onto the cell membrane. This would be analogous to what
happens in colorectal cancers (Lastraioli et al, 2004), where the
herg1 gene and hERG1 protein expression mark metastatic Dukes’
D cancers. A definitive conclusion, however, is more difficult to
reach for all gliomas, because the majority of surgical specimens
represent high-grade GBM.
While in many other human cancers hERG1 activity contributes
to the regulation of either cell proliferation or invasion, in GBM
cells the activity of hERG1 channels seems to be related
to a different aspect of tumour cell progression, that is,
neoangiogenesis. This would occur through the modulation of
VEGF secretion, which was inhibited when hERG1 channel activity
was specifically blocked. Our data also suggest that the mechanism
whereby hERG1 channels stimulate secretion depends on a
modulation at the mRNA level, similarly to what we have
previously reported in leukaemia cells for the calcitonin receptor
(Hofmann et al, 2001).
Providing further evidence confirming that hERG1 exerts
proangiogenic effects will require studies carried out in conditions
of hypoxia: poor blood supply and reduced O2 tension are often
associated with malignant gliomas. In these conditions, hERG1
channel activity is upregulated (Fontana et al, 2001) and VEGF
secretion is stimulated as a result of activation of the HIF pathway
(Semenza, 2004).
Finally, does the regulatory effect of hERG1 depend on
K
þ current flow or is it triggered by a conformational change
of the channel protein independently from the consequent
biophysical effects? Since the ion selectivity and the voltage
dependence of hERG1 and hELK2 are very similar, if the signaling
pathways that lead to VEGF secretion were triggered by a
biophysical effect, we would expect that individual gliomas
selected either hERG1 or hELK2 expression, indifferently. Our
data show instead that hERG1 largely prevails. Moreover, data on
U138 cells suggest that helk2 does not substitute for herg1.
Therefore, it seems that secretion is stimulated by unknown
regulatory effects triggered by hERG1 (and not by other K
þ
channels), although ion currents may have an effect of their own.
In other contexts, hERG1 channels are known to interact with
other membrane proteins with signalling function. We have
recently shown that hERG1 is physically linked to beta1 integrins
and thereby modulate adhesion-dependent signaling (Cherubini
et al, 2005).
Nonetheless, our observations lend further support to the idea
that hERG1 channels should be included among the molecular
markers of gliomagenesis and possible targets for novel anti-
tumour therapies.
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